SCHEMBL4606992

SCHEMBL4606992

COC(=O)C1=NN(c2ccc(Cl)cc2Cl)C(c2ccc(Br)s2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 8/20 0.45
CNR2 P34972 8/20 0.45
GABRA2 P47869 2/20 0.40
GABRB2 P47870 2/20 0.40
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
CXCR5 P32302 1/20 0.35
APLNR P35414 1/20 0.35
CCR6 P51684 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14621419 0.90 CNR1 (0.46) CNR1CNR2GABRA2GABRB2KDM4E
SCHEMBL4606740 0.90 CNR1 (0.46) CNR1CNR2GABRA2GABRB2KDM4E
SCHEMBL4605564 0.89 GABRA2 (0.45) CNR1CNR2GABRA2GABRB2KDM4E
SCHEMBL17158099 0.88 ALDH1A1 (0.38) CNR1CNR2KDM4EALDH1A1GAA
SCHEMBL4606276 0.88 CNR1 (0.46) CNR1CNR2GABRA2GABRB2
SCHEMBL4606907 0.87 CNR1 (0.46) CNR1CNR2GABRA2GABRB2KDM4E
SCHEMBL4605560 0.86 CNR1 (0.40) CNR1CNR2
SCHEMBL4605643 0.85 CNR1 (0.48) CNR1CNR2
SCHEMBL2018106 0.82 CNR1 (0.56) CNR1CNR2GABRA2GABRB2KDM4E
SCHEMBL17157569 0.82 ALDH1A1 (0.36) KDM4EALDH1A1GAAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP claimed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP claimed
EP-1743894-A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP claimed
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1743894-A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed
EP-1743894-A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed